Nutritional composition for promoting brain development and uses

Abstract

The present application belongs to the technical field of nutrient research, and particularly relates to a nutrient composition for promoting brain development and use thereof. The nutrient composition provided by the present application comprises two necessary components: i) lysophosphatidylethanolamine; and ii) N-acetylneuraminic acid. In the nutrient composition, the mass ratio of the lysophosphatidylethanolamine to the N-acetylneuraminic acid is 1:(1-800). The combination of lysophosphatidylethanolamine and N-acetylneuraminic acid can effectively promote the overall growth and development of the body, especially the brain development, and increase the expression levels of brain-derived neurotrophic factor and glial cell-derived neurotrophic factor in brain tissue, thereby effectively assisting the improvement of cognitive ability.

Description

Technical Field

[0001] This invention belongs to the field of nutrient research technology and relates to a nutrient composition that promotes brain development and its uses. Background Technology

[0002] Brain development is a complex and multi-factor-regulated dynamic process that spans the entire period from fetal development to adolescence. The period from 0 to 6 years of age is a critical window for the rapid proliferation of synapses and the construction of neural networks in the brain. The quality of development during this stage directly determines an individual's lifelong cognitive abilities, learning abilities, emotional regulation abilities, and the integrity of their nervous system function. Cognitive function, as the core of higher neural activity in the brain, refers to a series of complex abilities for an individual to acquire, process, store, and utilize information, encompassing key psychological processes such as learning, memory, attention, decision-making, and problem-solving. For children and adolescents, healthy cognitive development directly affects their learning efficiency (such as attention and memory), emotional and behavioral performance, social skills, and future ability to live independently.

[0003] Currently, cognitive training is a method used to improve cognition. However, for children and adolescents, behavioral training may increase the financial burden on families and also place significant psychological stress on parents.

[0004] Therefore, if nutritional supplements can be developed that are suitable for long-term use by individuals in early life, as well as children and adolescents, and that effectively promote brain development and enhance cognitive abilities, it will be of great significance in improving the health of people throughout their entire life cycle.

[0005] Phospholipids are key bioactive components in breast milk lipids, playing a crucial role in the development of the nervous system and metabolic regulation in infants and young children. Phospholipids can be broadly classified into two categories: glycerophospholipids (PL) and sphingomyelins (SM). PL can be further subdivided into lysophospholipids (LPL) and phosphatidylacetals. Lysophospholipids are produced through the hydrolysis of one fatty acid in the PL molecule, and the main components in breast milk are lysophosphatidylcholine (LPC) and lysophosphatidylethanolamine (LPE).

[0006] N-acetylneuraminic acid (Neu5Ac), also known as sialic acid (SA), is an acetylated derivative of the acidic glyconeuraminic acid. Neu5Ac is widely distributed in mammalian tissues and is a component of the oligosaccharide chains of mucins, glycoproteins, and glycolipids. It occupies the terminal non-reducing positions of complex carbohydrate oligosaccharides and is linked to the inner and outer surfaces of cell membranes in various ways. Neu5Ac is abundant in the human central nervous system and breast milk, with breast milk containing 0.25-1.50 g / L. Neu5Ac is also found in bird's nest, casein, milk, and eggs. SA has important physiological functions, such as promoting nervous system and brain development, regulating the reproductive and immune systems, inhibiting cancer cell metastasis, anti-free radical oxidation, promoting mineral and vitamin absorption, and promoting bone development. Summary of the Invention

[0007] The problem the invention aims to solve

[0008] In order to support brain development from early life and thus provide a good foundation for brain and cognitive health throughout the life cycle, this invention has conducted extensive research and provides a naturally sourced nutritional composition, mainly comprising lysophosphatidylethanolamine and N-acetylneuraminic acid. The two work synergistically to promote brain development and cognitive enhancement in early life groups such as infants and children, without any side effects, and can be consumed long-term as a nutritional supplement.

[0009] Solution for solving the problem

[0010] To address the aforementioned technical problems, the present invention provides the following technical solution:

[0011] [1]. A nutritional composition comprising the following two essential components:

[0012] i) Lysophosphatidylethanolamine;

[0013] ii) N-acetylneuraminic acid;

[0014] Furthermore, in the nutritional composition, the mass ratio of the lysophosphatidylethanolamine to the N-acetylneuraminic acid is 1:(1-800).

[0015] [2]. The nutritional composition according to [1], wherein the lysophosphatidylethanolamine comprises at least a lysophosphatidylethanolamine having a fatty acid chain of 12-22 carbon atoms connected at the sn-1 position.

[0016] [3]. The nutritional composition according to [1] or [2], wherein the fatty acid chain in the lysophosphatidylethanolamine is unsaturated.

[0017] [4]. The nutritional composition according to any one of [1]-[3], wherein the lysophosphatidylethanolamine is provided in the form of dairy products containing it and / or enzymatically hydrolyzed soybean lecithin.

[0018] [5]. The nutritional composition according to any one of [1]-[4], wherein the N-acetylneuraminic acid is provided in the form of a natural source and / or a synthetic source and / or a biofermentation source.

[0019] [6]. Use of the nutritional composition according to any one of [1]-[5] in the preparation of products that contribute to body growth and / or brain development.

[0020] [7]. According to the use described in [6], the contribution to brain development includes the contribution to cognitive ability enhancement.

[0021] [8]. According to the use described in [6] or [7], wherein the aid to brain development includes aiding in increasing the expression levels of brain-derived neurotrophic factor and / or glial cell-derived neurotrophic factor in brain tissue.

[0022] [9]. Use of the nutritional composition according to any one of [1]-[5] in the preparation of products that help improve cognitive abilities or help increase the expression levels of brain-derived neurotrophic factor and / or glial cell-derived neurotrophic factor in brain tissue.

[0023]

[10] . Use according to any one of [6]-[9], wherein the product contains any one or more of the following ingredients: plant-based ingredients, animal dairy ingredients, animal meat ingredients, functional additives and any acceptable excipients.

[0024] The effects of the invention

[0025] This invention proposes for the first time that the combination of lysophosphatidylethanolamine and N-acetylneuraminic acid has a synergistic effect in promoting brain development. In particular, when the two are combined in a certain proportion, they can synergistically promote the overall growth and development of the body, as well as increase the expression levels of brain-derived neurotrophic factor and glial cell-derived neurotrophic factor in brain tissue, effectively assisting in the improvement of cognitive abilities.

[0026] Meanwhile, the nutrients mentioned in this invention, lysophosphatidylethanolamine and N-acetylneuraminic acid, both have good safety profiles and are suitable for long-term use by people throughout their entire life cycle. They can be added to various types of products such as food, nutritional products, nutritional supplements, health foods, and pharmaceuticals. Detailed Implementation

[0027] The following describes embodiments of the present invention, but the present invention is not limited thereto. The present invention is not limited to the various configurations described below, and various modifications can be made within the scope of the claims. Embodiments and examples obtained by appropriately combining the technical means disclosed in different embodiments are also included in the technical scope of the present invention.

[0028] <Terminology Definition>

[0029] In this invention, "comprising," "having," "including," or "containing" can mean included or open-ended, and does not exclude additional, uncited elements or method steps. At the same time, "comprising," "having," "including," or "containing" can also mean closed-ended, excluding additional, uncited elements or method steps.

[0030] In this invention, the meaning of "may" includes both performing a certain process and not performing a certain process.

[0031] In this invention, "optional" or "optionally" means that certain substances, components, execution steps, application conditions, etc., are used or not used.

[0032] In this invention, the numerical ranges represented by "value A ~ value B", "value A - value B", and "value A above / below" refer to the ranges including the endpoint values ​​A and B.

[0033] In this invention, the term "about" is used to define that the numerical ranges and parameters of this invention are approximate values, and the relevant values ​​in the specific embodiments have been presented as precisely as possible. Unless otherwise explicitly stated, it should be understood that all ranges, quantities, values, and percentages used in this invention are modified by the term "about". Here, "about" generally means that the actual value is within ±5%, ±3%, ±1%, or ±0.5% of a specific value or range. Furthermore, the values ​​and ranges appearing in this invention should be understood to include systematic errors that are unavoidable in industrial production.

[0034] In this invention, terms such as "some specific / preferred embodiments," "other specific / preferred embodiments," and "implementation" refer to specific elements (e.g., features, structures, properties, and / or characteristics) related to a particular embodiment that are included in at least one of the embodiments described herein, and may or may not be present in other embodiments. Furthermore, it should be understood that these elements may be combined in any suitable manner in various embodiments.

[0035] In this invention, all unit names used are international standard unit names, and unless otherwise stated, the "%" used refers to weight or mass percentage content.

[0036] In this invention, "infants and toddlers" refers to the human group under the age of 3 years, including infants aged 0-6 months, older infants aged 6-12 months, and toddlers aged 12-36 months.

[0037] In this invention, "children" refers to the human group aged 3-6 years.

[0038] In this invention, "teenagers" refers to the human group aged 7-18.

[0039] In this invention, "young adult" refers to the human group aged 19-40.

[0040] In this invention, "pregnant women" includes women who are pregnant and women who are breastfeeding.

[0041] In this invention, "middle-aged and elderly" refers to the human group aged 41 and above, including middle-aged people aged 41-65 and elderly people aged 65 and above.

[0042] In this invention, "animal milk" refers to the liquid obtained from the mammary glands of a mammal in the process of lactation.

[0043] In this invention, "lysophosphatidyl ethanolamine (LysoPE, LPE)" is a glycerophospholipid composed of a glycerol backbone, a fatty acid chain, a phosphate group, and an ethanolamine head group. Compared to phosphatidyl ethanolamine, it lacks a fatty acid chain at the sn-1 or sn-2 position of its glycerol backbone.

[0044] In this invention, for ease of description of glycerophospholipids, the following characters are used to refer to different types of fatty acids: straight-chain fatty acids with a chain length of 18 carbon atoms and no carbon-carbon double bonds (18:0), such as stearic acid; straight-chain fatty acids with a chain length of 18 carbon atoms and one carbon-carbon double bond (18:1), such as oleic acid; straight-chain fatty acids with a chain length of 18 carbon atoms and two carbon-carbon double bonds (18:2), such as linoleic acid; and other fatty acid chain lengths are treated similarly. In this invention, for specific lysophosphatidylethanolamines, the format "LPE + the above characters" is used to indicate the type of lysophosphatidylethanolamine with different fatty acid chains, such as LPE 18:0, LPE 18:1, LPE 18:2, etc.

[0045] In this invention, "LPE(18:2(9Z,12Z) / 0:0)" refers to a lysophosphatidylethanolamine molecule characterized by the following structural features: linoleic acid (18:2(9Z,12Z)) is attached to the sn-1 position of glycerol, while a hydroxyl group (-OH) is present at the sn-2 position, indicating that this position does not contain a fatty acid chain (represented as 0:0). Here, 18:2(9Z,12Z) represents a fatty acid chain consisting of 18 carbon atoms and containing two cis double bonds (located at the 9th and 12th carbon atoms, respectively), i.e., linoleic acid; 0:0 indicates that the corresponding position lacks a fatty acid chain and is replaced by a hydroxyl group.

[0046] In this invention, N-acetylneuraminic acid, also known as sialic acid, can be abbreviated as SA, and its molecular formula is C. 11 H 19 NO.9

[0047] Unless otherwise defined, other technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.

[0048] (Nutritional composition)

[0049] The nutritional composition of the present invention comprises the following two essential components: i) lysophosphatidylethanolamine and ii) N-acetylneuraminic acid;

[0050] Furthermore, in the nutritional composition, the mass ratio of the lysophosphatidylethanolamine to the N-acetylneuraminic acid is 1:(1-800).

[0051] This invention does not impose special requirements on the source of lysophosphatidylethanolamine, as long as its source or form of use meets the requirements of local laws and regulations. For example, it can be prepared through physical separation and extraction, chemical synthesis, enzymatic hydrolysis, and biosynthesis. It can be isolated and extracted from phospholipid-rich milk sources, or natural phosphatidylethanolamine or natural phospholipids containing phosphatidylethanolamine can be enzymatically hydrolyzed using phospholipases. For example, deacetylation using phospholipase A2 can yield sn-1-acyl-LPE. Furthermore, lysophosphatidylethanolamine with a specific acyl group composition can be obtained using a combination of methods, such as a chemical-enzyme hybrid method.

[0052] In some embodiments, the lysophosphatidylethanolamine of the present invention can be separated and extracted from a phospholipid-rich milk source, wherein the phospholipid-rich milk source can be a milk fat globule membrane, and the separation and extraction method can be membrane separation.

[0053] In some embodiments, the lysophosphatidylethanolamine of the present invention is provided in the form of dairy products containing it (e.g., buttermilk products, phospholipid-containing milk proteins, milk phospholipid products, whole milk, whole milk powder, and / or phospholipid-containing cream products, etc.) and / or enzymatically hydrolyzed soybean lecithin. The content of lysophosphatidylethanolamine varies in each source form. For example: in the buttermilk products, the content of lysophosphatidylethanolamine, on a dry weight basis, can be 1-3000 mg / 100g, preferably 1-1000 mg / 100g; wherein the content of LPE (18:2(9Z,12Z) / 0:0) can be 1-1000 mg / 100g, preferably 10-500 mg / 100g; in the phospholipid-containing milk proteins, the content of lysophosphatidylethanolamine, on a dry weight basis, can be 0.1-1000 mg / 100g, preferably 0.5-500 mg / 100g. 0g; wherein the content of LPE (18:2(9Z,12Z) / 0:0) can be 0.1-300mg / 100g, preferably 0.5-200mg / 100g; in the phospholipid-containing cream product, on a dry weight basis, the content of lysophosphatidylethanolamine can be 0.0001-100mg / 100g liquid, preferably 0.001-50mg / 100g liquid; wherein the content of LPE (18:2(9Z,12Z) / 0:0) can be 0.0001-1mg / 100g liquid, preferably 0.0005-0.5mg / 100g liquid.

[0054] In other embodiments, the lysophosphatidylethanolamine of the present invention is provided in pure form (commercially available product) with a purity of 99% or higher.

[0055] This invention does not impose any particular limitation on the source of N-acetylneuraminic acid, as long as its source or form of use meets the requirements of local laws and regulations. Typically, it can be extracted from natural resources containing sialic acid, such as bird's nest, eggs, and milk; or it can be synthesized through chemical and enzymatic methods, such as condensing N-acetylglucosamine with the potassium salt of di-tert-butyloxosuccinic acid and decarboxylating it under alkaline catalysis to generate N-acetylneuraminic acid, or producing N-acetylmannosamine by catalyzing N-acetylneuraminic acid aldolase; or it can be obtained through fermentation by suitable microorganisms such as Escherichia coli and Bacillus subtilis; or it can be obtained through whole-cell synthesis.

[0056] In some embodiments, the N-acetylneuraminic acid described in this invention is provided in the form of natural and / or synthetic and / or biofermentation sources. Examples include N-acetylneuraminic acid products isolated from animal milk or milk raw materials, chemically synthesized N-acetylneuraminic acid products, and fermentation products of N-acetylneuraminic acid-producing microorganisms. For example, the N-acetylneuraminic acid content in each source form is typically 95-100% by mass.

[0057] In some embodiments, the N-acetylneuraminic acid can be prepared in-house or obtained commercially.

[0058] In some embodiments, the necessary component shown in i) comprises at least a lysophosphatidylethanolamine with a fatty acid chain of 12-22 carbon atoms attached to the sn-1 position, such as LPE14:1, LPE16:0, LPE17:1, LPE17:2, LPE18:0, LPE18:1, LPE18:2, LPE22:1, LPE22:2 and / or LPE22:6 present in milk sources; preferably, the necessary component shown in i) comprises at least a lysophosphatidylethanolamine with a fatty acid chain of 18 carbon atoms attached to the sn-1 position; preferably, the fatty acid chain in the lysophosphatidylethanolamine is unsaturated.

[0059] In some preferred embodiments, the lysophosphatidylethanolamine contains at least LPE (18:2(9Z,12Z) / 0:0). This invention has found that the combination of LPE (18:2(9Z,12Z) / 0:0) and N-acetylneuraminic acid can exert a synergistic effect that promotes growth and brain development.

[0060] In some embodiments, lysophosphatidylethanolamine and N-acetylneuraminic acid, comprising a fatty acid chain with a length of 12-22 carbon atoms linked at the sn-1 position, are the main active ingredients of the nutritional composition. That is, the nutritional composition of the present invention primarily relies on the lysophosphatidylethanolamine and N-acetylneuraminic acid, comprising a fatty acid chain with a length of 12-22 carbon atoms linked at the sn-1 position, to exert specific physiological activities, such as promoting body growth and brain development. In other words, in some embodiments, the active ingredients of the nutritional composition (the ingredients that exert specific physiological activities, i.e., those that promote body growth and brain development) consist of lysophosphatidylethanolamine and N-acetylneuraminic acid, comprising a fatty acid chain with a length of 12-22 carbon atoms linked at the sn-1 position.

[0061] In some specific embodiments, the active ingredient of the nutritional composition comprises, or is composed of, lysophosphatidylethanolamine and N-acetylneuraminic acid, a fatty acid chain of 18 carbon atoms linked at the sn-1 position.

[0062] In some preferred embodiments, the active ingredient of the nutritional composition comprises, or is composed of, lysophosphatidylethanolamine and N-acetylneuraminic acid, an unsaturated fatty acid chain of 18 carbon atoms linked at the sn-1 position.

[0063] In some preferred embodiments, the active ingredients of the nutritional composition comprise, or consist of, LPE (18:2(9Z,12Z) / 0:0) and N-acetylneuraminic acid.

[0064] In some embodiments, the nutritional composition comprises an active ingredient (a component that performs a specific physiological function, i.e., a component that contributes to body growth and brain development) and an inactive ingredient (a substance that does not contribute to body growth and brain development, or at least does not synergize with LPE (18:2(9Z,12Z) / 0:0) or N-acetylneuraminic acid). Exemplarily, the inactive ingredient may be other nutrients, any food-acceptable excipient, and / or substances that are generated during the production or acquisition of the active ingredient and cannot be effectively separated from or do not require separation from the active ingredient. In some embodiments, the nutritional composition consists of the active ingredient and the inactive ingredient.

[0065] In some embodiments, in the nutritional composition, the mass ratio of the necessary component shown in i) to the necessary component shown in ii) is 1:(1-800), for example, it can be 1:1, 1:5, 1:7.82, 1:10, 1:15, 1:16, 1:18, 1:20, 1:22, 1:25, 1:28, 1:30, 1:31.2, 1:32, 1:34, etc. 1:36, 1:38, 1:39.1, 1:40, 1:42, 1:44, 1:46, 1:48, 1:50, 1:55, 1:60, 1:64, 1:70, 1:75, 1:80, 1:85, 1:90, 1:95, 1:100, 1:110, 1:120, 1:125, 1:130, 1:140, 1:150, 1:1 56, 1:160, 1:170, 1:180, 1:190, 1:200, 1:210, 1:220, 1:230, 1:240, 1:250, 1:260, 1:270, 1:280, 1:290, 1:300, 1:400, 1:500, 1:600, 1:625, 1:650, 1:700, 1:800, etc.; preferably, the mass ratio of the two is 1:(5-650); more preferably, the mass ratio of the two is 1:(5-200); even more preferably, the mass ratio of the two is 1:(30-150); further preferably, the mass ratio of the two is 1:(100-150); preferably, the above ratio is the mass ratio of LPE (18:2(9Z,12Z) / 0:0) to N-acetylneuraminic acid. Within the above mass ratio range, the essential components shown in i) (especially LPE (18:2(9Z,12Z) / 0:0)) and the essential components shown in ii) work synergistically to contribute to growth and / or brain development.

[0066] The present invention does not impose any particular limitation on the form of the nutritional composition; typically, it can be a liquid or a solid. From the perspective of ease of production, transportation, storage, and use, the nutritional composition of the present invention is preferably a powdered solid.

[0067] (Uses of the nutritional composition)

[0068] This invention provides the use of the above-described nutritional composition in promoting body growth and / or brain development. In some embodiments, the promotion of body growth and brain development is not for the purpose of preventing or treating diseases; that is, this invention provides the use of the above-described nutritional composition for non-therapeutic purposes in promoting body growth and / or brain development. Based on this, this invention also provides the use of the above-described nutritional composition in the preparation of products that promote body growth and / or brain development.

[0069] In some implementations, the contribution to brain development includes the contribution to cognitive ability enhancement; preferably, the contribution to cognitive ability enhancement includes the contribution to spatial cognitive ability enhancement.

[0070] In some embodiments, the aid to brain development includes aiding in increasing the expression levels of brain neurotrophic factors; preferably, the brain neurotrophic factors include brain-derived neurotrophic factor and / or glial cell-derived neurotrophic factor.

[0071] In some more specific embodiments, the aid to brain development includes helping to increase the expression levels of brain-derived neurotrophic factor (BDNF) and / or glial cell-derived neurotrophic factor (GNF) in brain tissue; preferably, the aid to brain development includes helping to increase the expression levels of BDNF and GNF in brain tissue; more preferably, the aid to brain development includes helping to increase the gene expression levels of BDNF and GNF in brain tissue; and even more preferably, the aid to brain development includes helping to increase the mRNA levels of BDNF and GNF genes in brain tissue.

[0072] Based on this, the present invention also provides the use of the above-mentioned nutritional composition in the preparation of products that help improve cognitive abilities (preferably spatial cognitive abilities) and help increase the expression levels of brain-derived neurotrophic factor or glial cell-derived neurotrophic factor in brain tissue.

[0073] The present invention does not specifically limit the products containing or prepared from the above-described nutritional composition, such as food products. When the product is a food product, the components of the nutritional composition are used in a source or form that meets the requirements of local laws and regulations. Specifically, the lysophosphatidylethanolamine in the nutritional composition is provided in the form of dairy products containing it (e.g., buttermilk products, phospholipid-containing milk proteins, milk phospholipid products, whole milk, whole milk powder, and / or phospholipid-containing cream products, etc.) and / or enzymatically hydrolyzed soybean lecithin, and is added to the food.

[0074] In some implementation schemes, the food is infant food, children's food, adolescent food, pregnant and postpartum food, young and middle-aged food, or middle-aged and elderly food.

[0075] In some embodiments, the food product of this invention is a confectionery, such as hard candy, gel candy, shortbread candy, compressed candy, and aerated candy. In some embodiments, the food product of this invention is a beverage, such as carbonated beverages, tea beverages, coffee beverages, fruit and vegetable juice beverages, and lactic acid bacteria beverages. In some embodiments, the food product of this invention is a dairy product, such as milk powder, cheese, fermented milk, and liquid milk. In some embodiments, the food product of this invention is a baked product, such as bread, cakes, and biscuits. In some embodiments, the food product of this invention is a dietary supplement, such as hard capsules, soft capsules, tablets, oral liquids, pills, granules, and powders.

[0076] In some embodiments, the food described in this invention is in the form of a liquid or a solid under normal temperature conditions.

[0077] In some embodiments, in the food described in this invention, the mass ratio of the necessary component shown in i) to the necessary component shown in ii) can be 1:(1-800); preferably, the mass ratio can be 1:(5-650); more preferably, the mass ratio can be 1:(5-200); even more preferably, the mass ratio can be 1:(30-150); further preferably, the mass ratio can be 1:(100-150); preferably, the above ratio is the mass ratio of LPE (18:2(9Z,12Z) / 0:0) to N-acetylneuraminic acid.

[0078] This invention does not impose any specific absolute limits on the content of lysophosphatidylethanolamine, LPE (18:2(9Z,12Z) / 0:0) and N-acetylneuraminic acid in food, as long as the requirements of local food-related laws and regulations are met.

[0079] In some embodiments, the content of LPE (18:2(9Z,12Z) / 0:0) in the food, based on the total dry matter content of the food, can be 0.1-1000 mg / 100g, preferably 0.5-500 mg / 100g, more preferably 1-100 mg / 100g; the content of N-acetylneuraminic acid can be 1-1000 mg / 100g, preferably 10-800 mg / 100g, more preferably 20-400 mg / 100g.

[0080] In addition to the components described above in the nutritional composition, the food may also contain other ingredients, such as common food ingredients like proteins / amino acids, carbohydrates, fats, vitamins, and minerals.

[0081] In addition, depending on the type of food and the end needs of the target audience, in some embodiments, the food may also contain one or more of the following ingredients: plant-based ingredients, animal dairy ingredients, animal meat ingredients, functional additives, and any acceptable excipients.

[0082] Examples of plant-based ingredients include fruits such as figs, pomegranates, kiwis, oranges, tangerines, pineapples, strawberries, apples, bananas, grapes, pears, cherries, blueberries, blackberries, blackcurrants, cranberries, raspberries, melons, amla, and bilberries, or their extracts; vegetables such as onions, cucumbers, tomatoes, cauliflower, carrots, spinach, kale, Brussels sprouts, garlic, basil, and oregano, or their extracts; grains such as rice (indica, japonica, glutinous rice), cereals (wheat, barley, oats, rye), corn, sorghum, millet, sorghum, yellow millet, buckwheat, soybeans, broad beans, peas, mung beans, red beans, and kidney beans, or their extracts; nuts such as walnuts, pistachios, cashews, hazelnuts, almonds, apricot kernels, pine nuts, peanuts, sunflower seeds, chestnuts, macadamia nuts, and ginkgo nuts, or their extracts; coffee or its extracts; and some medicinal and edible herbal medicines or their extracts.

[0083] Animal dairy product ingredients can include fresh milk from mammals such as cows, sheep, and camels, as well as reprocessed dairy products such as whole milk powder, skim milk powder, whey protein concentrate, desalted whey powder, whey protein powder, hydrolyzed whey protein powder, and casein powder.

[0084] Examples of animal meat product ingredients include pork, beef, mutton, seafood, and poultry.

[0085] Examples of functional additives include vitamin supplements (such as vitamin A, beta-carotene, vitamin D3, vitamin E, vitamin K1, vitamin B1, vitamin B2, vitamin B6, and vitamin B1). 12 Supplements include: Vitamin C, pantothenic acid, folic acid, niacin, biotin, etc.; mineral supplements (e.g., calcium, iron, copper, manganese, zinc, magnesium, fluorine, sodium, potassium, selenium, iodine, etc.); nucleotide supplements (e.g., disodium 5'-cytidine, disodium 5'-uridine, adenosine monophosphate, disodium 5'-guanylate, disodium 5'-inosine, etc.); dietary fiber (e.g., inulin, konjac flour, galactooligosaccharides, fructooligosaccharides, isomaltooligosaccharides, soybean polysaccharides, cyclodextrin, resistant dextrin, soybean fiber, etc.); and polyunsaturated fatty acid supplements (e.g., docosahexaenoic acid, eicosapentaenoic acid, eicosapentaenoic acid, etc.).

[0086] Any acceptable excipients may include solvents, antioxidants, antibacterial agents, thickeners, diluents, cosolvents, stabilizers, emulsifiers, fillers, disintegrants, lubricants, coating materials, anti-caking agents, flavoring agents, sweeteners, food flavorings, and food colorings.

[0087] Example

[0088] The embodiments of the present invention will be described in detail below with reference to examples. However, those skilled in the art will understand that the following examples are for illustrative purposes only and should not be considered as limiting the scope of the invention. Unless otherwise specified in the examples, conventional conditions or conditions recommended by the manufacturer are followed. Reagents or instruments whose manufacturers are not specified are all commercially available conventional products.

[0089] The experimental equipment used in the experimental examples of this invention includes: a dissecting microscope (SZX7, OLYMPUS, Japan), a CCD camera (VertA1, Shanghai Tusen Vision Technology Co., Ltd.), a precision electronic balance (CP214, OHAUS, USA), a fully automated rapid sample grinder (JXFSTPRP-24L, Shanghai Jingxin Experimental Equipment Technology Department), a fully automated nucleic acid extractor (Auto-Pure32A, Hangzhou Aosheng Instrument Co., Ltd.), a conventional PCR amplification instrument (T100, BIO-RAD, Singapore), a real-time PCR instrument (CFX Connect, BIO-RAD, Singapore), and a high-speed refrigerated centrifuge (Heraeus). Fresco 17 (Thermo Fisher, Germany), UV-Vis spectrophotometer (Nanodrop 2000, Thermo, USA), microplate mini centrifuge (BE-6100, Haimen Qilin Bell Instrument Manufacturing Co., Ltd.), optical adhesive sealing film B (MSB1001, Bio-rad, USA), low-skirted 96-well plate (transparent) (HSP9601, Bio-rad, USA).

[0090] The experimental materials and reagents used in the experimental examples of this invention include: LPE18:2 (LPE(18:2(9Z,12Z) / 0:0)) provided by Heilongjiang Feihe Dairy Co., Ltd.; N-acetylneuraminic acid (SA) provided by Jiabiyou Co., Ltd.; positive control drug: Ginkgo biloba and Cistanche deserticola tablets; dimethyl sulfoxide (DMSO, batch number 20250624, Sinopharm Chemical Reagent Co., Ltd.); ChamQ Universal SYBR qPCR Master Mix (batch number 027E2201CD, Vazyme); Hifair III 1st StrandcDNA Synthesis SuperMix for qPCR (batch number H9305270, Yisheng Biotechnology (Shanghai) Co., Ltd.); and pre-loaded magnetic bead universal RNA extraction kit C (catalog number TL2402001643C, Foshan Aowei Biotechnology Co., Ltd.).

[0091] The experimental animals used in the experimental examples of this invention are wild-type AB strain zebrafish.

[0092] In the experimental examples of this invention, data processing was performed using SPSS 26.0 software for statistical analysis. The data were described by mean ± standard error (mean ± SE), and p < 0.05 was used as the significance level.

[0093] Experiment Example 1: Dose-response assessment of the effects of two nutrient interventions on the cognitive development of zebrafish

[0094] Zebrafish share high similarities with humans in brain physiology, anatomy, and neurochemistry. The zebrafish brain structure includes the telencephalon, diencephalon, midbrain, cerebellum, and medulla oblongata. Its cell types (such as astrocytes, microglia, and oligodendrocytes) and major neurotransmitter systems (such as GABA, acetylcholine, and serotonin) are similar to those in humans. Studies have shown that zebrafish possess an amygdala structure homologous to mammals and have functions similar to those in humans in regulating emotions, controlling learning, and memory. Mazes are important experimental tools for assessing various behavioral manifestations (such as learning and memory, anxiety, and preferences) in zebrafish neurological disease models. Various cognitive tasks are often conducted in mazes using color cues to study zebrafish learning and memory functions. Zebrafish prefer short-wavelength colors and show a strong preference for blue compared to other colors (such as red, green, and yellow). Therefore, this study uses the percentage (%) of the distance zebrafish travel within the blue area relative to the total distance traveled in the entire area as an indicator of the role of nutrients in promoting brain development.

[0095] 1. Determination of the maximum tolerated concentration (MTC) of two nutrients in zebrafish

[0096] This experiment first determined the maximum tolerable concentration (MTC) of two nutrients in zebrafish. The specific steps are as follows:

[0097] Zebrafish strain: Wild-type AB strain zebrafish, 30 fish in each experimental group, incubated in an incubator at 28℃.

[0098] Experimental groups: Two samples were set up (LPE18:2 and SA), with 9 detection concentrations for LPE18:2 and 5 detection concentrations for SA; a normal control group (normal zebrafish without any treatment or intervention) was also set up.

[0099] Experimental Methods: Wild-type AB strain zebrafish, 5 days post-fertilization (5 dpf), were randomly selected and placed in beakers, with 30 zebrafish treated in each beaker (each experimental group). Samples were administered via water-soluble administration, and a normal control group was also included. Each beaker had a volume of 20 mL. After treatment at 28℃ for 1 day, the mean chromosomal conversion ratio (MTC) of each sample relative to normal zebrafish was measured.

[0100] Experimental Results: As shown in Table 1, when the concentration of LPE18:2 was gradually increased from 0.0781 μg / mL to 1.25 μg / mL, the zebrafish condition was similar to that of the normal control group; when the concentration was further increased to 2.5 μg / mL, the zebrafish began to die; therefore, the MTC of LPE18:2 in the brain development promotion efficacy experiment was 1.25 μg / mL. For SA, when the concentration was increased from 125 μg / mL to 250 μg / mL, the zebrafish condition was similar to that of the normal control group; when the concentration was further increased to 500 μg / mL, the zebrafish began to die; therefore, the MTC of SA in the brain development promotion efficacy experiment was 250 μg / mL.

[0101] Table 1. Results of the concentration exploration experiment on the brain development-promoting effects of the samples (n=30)

[0102]

[0103] 2. Dose-response assessment of the effect of nutrient intervention on cognitive development in zebrafish

[0104] Zebrafish strain: Wild-type AB strain zebrafish, 30 fish in each experimental group, incubated in a 28℃ incubator.

[0105] Experimental groups: Five concentrations (MTC group, 1 / 2 MTC, 1 / 4 MTC, 1 / 8 MTC, 1 / 16 MTC) were set up for LPE18:2 and SA intervention groups respectively; one normal control group (normal zebrafish without any treatment or intervention) and one positive control group (zebrafish treated with 125 μg / mL Ginkgo biloba and Cistanche deserticola tablets) were also set up, for a total of 12 groups.

[0106] Experimental Methods: Wild-type AB strain zebrafish (5 dpf) were randomly selected and placed in beakers, with 30 zebrafish per beaker (each experimental group). Samples were administered via water-soluble administration. The positive control group received 125 μg / mL Ginkgo biloba and Cistanche deserticola tablets, and a normal control group was also included. Each beaker had a volume of 20 mL. After treatment at 28℃ for one day, 5 zebrafish from each experimental group were randomly selected and placed in a cross-shaped module. The module was divided into four areas: yellow, blue, red, and green. Six modules were placed in each group. Data were collected using a behavioral analyzer. The percentage (%) of the total movement distance of the zebrafish within the blue area relative to the total movement distance of the entire area within 10 minutes was analyzed. The statistical analysis results of this indicator were used to evaluate the dose-response relationship of the sample in promoting brain development.

[0107] Experimental results: As shown in Table 2, the proportion of the movement distance of zebrafish in the blue area in the normal control group was 43.61%; after intervention with Ginkgo biloba and Cistanche deserticola tablets, the proportion of the positive control group increased to 57.5%.

[0108] Under LPE18:2 intervention, five concentration gradients were set, with a maximum concentration of 1.25 μg / mL and each gradient halved sequentially. Results showed that the percentage of zebrafish movement distance within the blue region increased to varying degrees in each concentration group, rising from 45.89% at the lowest concentration of 0.0781 μg / mL to 63.42% at 1.25 μg / mL, exhibiting a clear dose-dependent effect. Significance analysis showed that, except for the lowest concentration (0.0781 μg / mL), the percentage of movement distance in all other concentration groups was significantly higher than that in the normal control group.

[0109] Under SA intervention, five concentration gradients were set up, with a maximum concentration of 125 μg / mL and each gradient halved sequentially. Results showed that the proportion of zebrafish movement distance within the blue region increased to varying degrees in each concentration group, but the overall increase was slightly lower than that of LPE18:2. Analysis of significant differences between groups showed no significant difference between SA at doses of 7.81 μg / mL, 15.6 μg / mL, and 31.2 μg / mL and the normal control group. However, at concentrations ranging from 62.5 to 125 μg / mL, the proportion of zebrafish movement distance within the blue region was significantly higher than that of the normal control group.

[0110] The results indicate that LPE18:2 can significantly improve the cognitive ability of zebrafish in the concentration range of 0.156-1.25 μg / mL; SA can also significantly improve the cognitive ability of zebrafish in the concentration range of 62.5-125 μg / mL.

[0111] Table 2. Effects of different doses of the two nutrients on the percentage of distance traveled by zebrafish in the blue area.

[0112]

[0113] Experiment Example 2: Effects of different nutrients and their combinations on the body length of zebrafish

[0114] Body length is one of the important indicators for evaluating the growth and development of zebrafish. Generally, the longer the body length, the better the overall development level of the zebrafish, which also indirectly reflects a better state of brain development.

[0115] To verify that LPE18:2 and SA have a synergistic effect on promoting brain development in zebrafish, this study set up different combinations of the two to analyze the effects of individual and combined nutrient interventions on zebrafish body length.

[0116] Experimental Groups: A normal control group, a positive control group, and sample treatment groups were set up (including Comparative Examples 1-5 and Examples 1-6). Zebrafish in the normal control group were cultured routinely without any treatment or intervention. The positive control group was treated with 125 μg / mL Ginkgo biloba and Cistanche deserticola tablets. Comparative Examples 1-2 were treated with 0.1 μg / mL and 0.5 μg / mL LPE18:2. Comparative Examples 3-5 were treated with 3.91 μg / mL, 15.6 μg / mL, and 62.5 μg / mL SA. Examples 1-6 were intervention groups consisting of LPE18:2 and SA mixed at different concentration ratios (1:7.82 to 1:625). Specific experimental group settings are shown in Table 3.

[0117] Table 3. Design schemes for promoting brain development with different nutrient ratios

[0118]

[0119] Experimental Methods: 3dpf wild-type AB strain zebrafish were randomly selected and placed in beakers, 30 fish per beaker (each experimental group). The samples were administered in water-soluble form. The positive control group received 125 μg / mL Ginkgo biloba and Cistanche deserticola tablets. A normal control group was also included. Each beaker had a volume of 20 mL. After treatment at 28℃ for 3 days, 10 zebrafish were randomly selected from each experimental group, photographed under a dissecting microscope, and data were collected using NIS-Elements D 3.20 advanced image processing software. The body length of the zebrafish was analyzed, and the statistical analysis results of this index were used to evaluate the efficacy of the samples in promoting brain development. The experimental results are shown in Table 4.

[0120] As shown in Table 4, the average body length of zebrafish in the normal control group was approximately 3.81 mm. After intervention with Ginkgo biloba and Cistanche deserticola tablets, the body length significantly increased to 3.96 mm. Intervention with LPE18:2 at low and high doses (Comparative Examples 1 and 2) also resulted in a further increase in zebrafish body length compared to the normal control group, but the differences were not statistically significant (p>0.05). Intervention with SA at low, medium, and high doses (Comparative Examples 3-5) resulted in varying degrees of increase in zebrafish body length compared to the normal control group, but the differences were not statistically significant (p>0.05).

[0121] In contrast, Examples 1-6 used compositions formed by combining LPE18:2 and SA in different proportions for combined intervention, and the results showed that the body length of zebrafish was further increased. Significant difference analysis showed that the body length of all six examples was significantly higher than that of the normal control group, and there was no significant difference compared with the positive control group. This indicates that the compositions formed by combining LPE18:2 and SA are more effective than either of them alone in promoting the overall growth and development of zebrafish.

[0122] Table 4. Effects of interventions with individual and combined nutrients on the body length of zebrafish

[0123]

[0124] Experiment Example 3: Effects of different nutrients and combinations on the cognitive abilities of zebrafish

[0125] Zebrafish strain: Wild-type AB strain zebrafish, 30 fish in each experimental group, incubated in a 28℃ incubator.

[0126] Experimental grouping: As shown in Table 3, 11 groups were set up for intervention with LPE18:2 and SA monomer and their different ratios. At the same time, one normal control group (normal zebrafish without any treatment or intervention) and one positive control group (zebrafish treated with 125 μg / mL Ginkgo biloba and Cistanche deserticola tablets) were set up.

[0127] Experimental Methods: Wild-type AB strain zebrafish, 5 days post-fertilization (5 dpf), were randomly selected and placed in beakers, with 30 zebrafish per beaker (each experimental group). Water-soluble samples were administered. The positive control group received 125 μg / mL Ginkgo biloba and Cistanche deserticola tablets, and a normal control group was also included. Each beaker had a volume of 20 mL. After treatment at 28℃ for 1 day, 5 zebrafish were randomly selected from each experimental group and placed in a cross-shaped module. This module was divided into four regions: yellow, blue, red, and green, with 6 modules per group. Data were collected using a behavior analyzer, and the percentage (%) of the total movement distance of the zebrafish within the blue region relative to the total movement distance of the entire region within 10 minutes was analyzed. The statistical analysis results of this indicator were used to evaluate the efficacy of the sample in promoting brain development and behavioral performance.

[0128] The experimental results are shown in Table 5, and the significance analysis of differences between groups is shown in Table 6.

[0129] As shown in Table 5, the average distance traveled by zebrafish in the blue area of ​​the cross maze in the normal control group was 44.18%. After intervention with Ginkgo biloba and Cistanche deserticola tablets, this percentage increased to 59.62% in the positive control group, indicating that the cognitive ability of the zebrafish was improved.

[0130] Comparative Examples 1 and 2 illustrate the percentage of movement distance in the blue area of ​​the cross maze in zebrafish after low and high dose intervention with LPE18:2. The results showed that the percentage of movement distance in both dose groups was increased to varying degrees compared with the normal control group. Statistical analysis showed no significant difference between the low-dose group (Comparative Example 1) and the high-dose group (Comparative Example 2) and the normal control group (p>0.05).

[0131] Comparative Examples 3-5 illustrate the percentage of movement distance in the blue area of ​​the cross maze in zebrafish after intervention with low, medium, and high doses of SA. The results showed that although the percentage of movement distance in each dose group was higher than that in the normal control group, the differences were not statistically significant (p>0.05). These results indicate that interventions with LPE18:2 and SA alone were ineffective.

[0132] Examples 1-6 demonstrate the effect of combining LPE18:2 and SA in different proportions on the proportion of movement distance in the blue region of zebrafish. Table 5 shows that after intervention with the combination of the two nutrients, the proportion of movement distance in the blue region of zebrafish was significantly higher than that of either nutrient alone. Significant difference analysis showed that the proportion of movement distance in the blue region in all six examples was significantly higher than that in the normal control group (p<0.0001), with no significant difference from the positive control group, and significantly higher than that in the five comparative examples (p values ​​are shown in Table 6). This indicates that the combined use of LPE18:2 and SA has a synergistic effect on improving the cognitive ability of zebrafish.

[0133] Further analysis revealed that the effects of all six examples were greater than the sum of the effects of the two nutrients alone at the same concentration, confirming that the combination of LPE18:2 and SA has a synergistic effect on increasing the proportion of zebrafish moving in the blue area.

[0134] Table 5. Effects of nutrient monomer and combination interventions on the proportion of movement in the blue area of ​​zebrafish in the cross maze.

[0135]

[0136] Table 6. Significant differences among zebrafish groups in the proportion of movement within the blue area of ​​the cross maze.

[0137]

[0138]

[0139] Experiment Example 4: Effects of different nutrients and combinations on the expression of genes related to brain development in zebrafish

[0140] Brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) are two crucial neurotrophic factors in brain development. BDNF primarily exerts its biological effects by binding to the TrkB receptor, exhibiting sustained high expression from the embryonic stage to postnatal life, and is widely distributed in key brain regions such as the hippocampus, cortex, and cerebellum. Its functions include promoting neurogenesis, neuronal differentiation, synapse formation, and neural circuit construction, and it plays a specific regulatory role in specific brain regions such as the hippocampus, cerebral cortex, and cerebellum. GDNF, on the other hand, functions through the GFRα1 / RET receptor complex signaling pathway, exhibiting high specificity for dopaminergic neurons and motor neurons. It is a core regulator of the midbrain dopamine system development, ensuring not only the normal development of motor neurons and the peripheral nervous system but also participating in the regulation of functions such as the enteric nervous system. Therefore, this study measured the gene expression levels of BDNF and GDNF in the brains of zebrafish under normal control, positive control, and different nutrient intervention conditions.

[0141] Zebrafish strain: Wild-type AB strain zebrafish, 30 fish in each experimental group, incubated in a 28℃ incubator.

[0142] Experimental grouping: As shown in Table 3, 11 groups were set up for intervention with LPE18:2 and SA monomer and their different ratios. At the same time, one normal control group (normal zebrafish without any treatment or intervention) and one positive control group (zebrafish treated with 125 μg / mL Ginkgo biloba and Cistanche deserticola tablets) were set up.

[0143] Experimental Methods: Wild-type AB strain zebrafish (5 dpf) were randomly selected and placed in beakers, with 30 fish per beaker (each experimental group). Samples were administered via water-soluble solution. The positive control group received 125 μg / mL Ginkgo biloba and Cistanche deserticola tablets, and a normal control group was also included. Each beaker had a volume of 20 mL. After treatment at 28℃ for one day, total RNA was extracted from each group of zebrafish using a pre-loaded magnetic bead-based universal RNA extraction kit. The concentration and purity of total RNA were determined using a UV-Vis spectrophotometer. 2.00 μg of total RNA was used to synthesize 20.0 μL of cDNA according to the cDNA first-strand synthesis kit instructions. The expression of β-ACTIN, BDNF, and GDNF genes was detected by real-time quantitative PCR (q-PCR). Primer sequences are shown in Table 7. β-ACTIN was used as an internal reference gene, and the relative RNA expression levels of BDNF and GDNF genes were calculated.

[0144] Table 7. Primer sequence information

[0145]

[0146] The experimental results are shown in Table 8, and the significance analysis of differences between groups is shown in Table 9.

[0147] As shown in Table 8, intervention with Ginkgo biloba and Cistanche deserticola tablets significantly increased the relative expression level of the BDNF gene in the brain tissue of normal zebrafish. Intervention with LPE18:2 and SA, respectively, also resulted in varying degrees of increase in BDNF gene expression compared to the normal control group. Statistical analysis revealed no significant difference between the low-dose LPE18:2 group (Comparative Example 1) and the low-dose SA group (Comparative Example 3) and the normal control group (p>0.05); however, at relatively high doses (Comparative Examples 2, 4, and 5), the relative expression level of the BDNF gene was significantly higher than that of the normal control group (p values ​​are shown in Table 9). This indicates that LPE18:2 and SA only promote BDNF gene expression in zebrafish brain tissue at certain doses.

[0148] Examples 1-6 investigated the effects of combinations of LPE18:2 and SA at different ratios on BDNF gene expression in normal zebrafish brain tissue. The results showed that the relative BDNF expression levels in all six examples were significantly higher than those in the normal control group (p<0.0001), and reached or exceeded those in the positive control group. Further analysis revealed that the BDNF expression levels in all six examples were significantly higher than those in the five comparative examples (p values ​​are shown in Table 9), and the effects of the six examples were significantly greater than the simple sum of the intervention effects of the two nutrients at equal concentrations, indicating a synergistic effect.

[0149] Meanwhile, this invention also found that after intervention with Ginkgo biloba and Cistanche deserticola tablets in normal zebrafish, the relative expression level of the GDNF gene in their brain tissue was significantly increased. Furthermore, intervention with LPE18:2 and SA, respectively, also resulted in varying degrees of increase in GDNF gene expression compared to the normal control group. Significant difference analysis showed that LPE18:2 significantly increased the relative expression level of GDNF in zebrafish brain tissue at both low and high doses (p<0.0001); while the low and medium dose SA groups (Comparative Example 3 and Comparative Example 4) showed no significant difference compared to the normal control group (p>0.05), with only the high dose group (Comparative Example 5) showing a significantly higher expression level than the normal control group (p<0.0001). This indicates that LPE18:2 is effective in promoting GDNF expression, while SA requires a certain dosage to be effective.

[0150] Examples 1-6 investigated the effects of combinations of LPE18:2 and SA at different ratios on GDNF gene expression in normal zebrafish brain tissue. The results showed that the relative GDNF expression levels in all six examples were significantly higher than those in the normal control group (p<0.0001), and reached or exceeded those in the positive control group. Further analysis revealed that the GDNF expression levels in all six examples were significantly higher than those in the five comparative examples (p values ​​are shown in Table 9), and the effects of the six examples were significantly greater than the simple sum of the intervention effects of the two nutrients at equal concentrations, further confirming the synergistic effect of the two substances.

[0151] In conclusion, combined intervention with LPE18:2 and SA can significantly promote the mRNA expression of neurotrophic factors BDNF and GDNF in brain tissue, and the two have a synergistic effect.

[0152] Table 8. Effects of nutrient monomers and combinations on the expression levels of neurotrophic factor genes in the zebrafish brain

[0153]

[0154] Table 9. Significant differences in the expression levels of neurotrophic factor genes in the brains of zebrafish among different groups.

[0155]

[0156]

Claims

1. A nutritional composition, characterized in that, The nutritional composition comprises the following two essential components: i) Lysophosphatidylethanolamine; ii) N-acetylneuraminic acid; Furthermore, in the nutritional composition, the mass ratio of the lysophosphatidylethanolamine to the N-acetylneuraminic acid is 1:(1-800).

2. The nutritional composition according to claim 1, characterized in that, The necessary component shown in i) contains at least lysophosphatidylethanolamine with a fatty acid chain of 12-22 carbon atoms linked at the sn-1 position.

3. The nutritional composition according to claim 1 or 2, characterized in that, The fatty acid chains in the lysophosphatidylethanolamine are unsaturated.

4. The nutritional composition according to any one of claims 1-3, characterized in that, The lysophosphatidylethanolamine is provided in the form of dairy products containing it and / or enzymatically hydrolyzed soybean lecithin.

5. The nutritional composition according to any one of claims 1-4, characterized in that, The N-acetylneuraminic acid is provided in the form of natural and / or synthetic and / or biofermentation sources.

6. Use of the nutritional composition according to any one of claims 1-5 in the preparation of products that contribute to body growth and / or brain development.

7. The use according to claim 6, characterized in that, The benefits to brain development include improvements in cognitive abilities.

8. The use according to claim 6 or 7, characterized in that, The benefits to brain development include helping to increase the expression levels of brain-derived neurotrophic factor and / or glial cell-derived neurotrophic factor in brain tissue.

9. Use of the nutritional composition according to any one of claims 1-5 in the preparation of products that help improve cognitive abilities or help increase the expression levels of brain-derived neurotrophic factor and / or glial cell-derived neurotrophic factor in brain tissue.

10. The use according to any one of claims 6-9, characterized in that, The product contains any one or more of the following ingredients: plant-based ingredients, animal dairy ingredients, animal meat ingredients, functional additives, and any acceptable excipients.

Images